Singapore: ImmunoScape Pte. Ltd., an ASTAR spin-out backed by Amgen Ventures and EDBI, has announced the execution of a Memorandum of Understanding (MOU) with a leading NCI-designated Comprehensive Cancer Center in the United States, known for its significant contributions to cellular immunotherapy. This collaboration aims to accelerate the clinical introduction of ImmunoScape's 'Seed and Boost' platform. Additionally, the company revealed a strategic investment from Leonardo DiCaprio.

According to BERNAMA News Agency, the MOU outlines a partnership between ImmunoScape and the cancer center to initiate an investigator-led clinical trial targeting Wilms Tumor 1 (WT1) positive solid tumors. The trial will specifically address four challenging indications: ovarian, mesothelioma, and other high-unmet need solid tumors such as pancreatic and colorectal cancers. The first patients are expected to receive doses by September 2026.